The signal
Around 2% of European adults are currently using GLP-1 treatments. Their effect on total European food demand is estimated at approximately -0.25%. That is marginal. Yet PepsiCo, Mondelēz, Hershey and Danone have all discussed adaptation strategies during recent earnings calls, while Nestlé has launched Vital Pursuit, a protein-forward range explicitly aimed at these consumers. In July, the European Protein Plan was also criticised for focusing too heavily on animal feed.
The disproportion is the signal. The immediate effect on aggregate demand remains limited, but the subject has reached senior leadership and innovation agendas. It is changing how food companies describe future needs before it materially changes total volumes.
What everyone is saying
The dominant interpretation is that satiety is becoming the new territory of food innovation, protein the category's leading nutrient — close to 60% of consumers say they want more of it — and rapid reformulation the obvious response. IFT FIRST 2026 captured this reading: GLP-1 is accelerating expectations already established around nutrient density, satiety, sustained energy and digestive support.
That reading is not wrong. It is simply incomplete. It treats GLP-1 primarily as a demand segment and reformulation brief, when its more immediate impact may be on the language available to brands.
What it really changes for brands
The gap between a 0.25% reduction in demand and the attention the issue receives should be a warning. Leadership teams are discussing GLP-1 not because it has already displaced substantial volume, but because it provides a vocabulary.
For fifteen years, “satisfying”, “nutrient dense” and “supports satiety” were soft, difficult-to-prove arguments, often confined to the back of the pack. The arrival of a class of medicines acting precisely on appetite and satiety has made this vocabulary legitimate, measurable and publicly discussable. This is not a nutrition revolution. It is a narrative release.
Two practical consequences follow.
The accelerated commoditisation of protein
When an entire category adds protein at the same time, protein stops being an argument. A nutrient claim can produce short-term relevance, but it cannot remain a position when every competitor makes it.
FrieslandCampina's native protein shake concept is interesting precisely because it does not rely on the nutrient alone. It combines protein with a 100% natural, two-ingredient formula, supply-chain transparency and simplicity. The combination differentiates, not the ingredient.
This is also where supply context matters. The European Commission reports that 74% of high-protein feed ingredients used in the EU are imported. Protein is not only a consumer claim; it is an agricultural and industrial system. Brands that reduce the subject to a front-of-pack number risk promising something they have not understood across the value chain.
The targeting trap
Reformulating a mass-market range for roughly 2% of adults is difficult to justify. Reformulating on the assumption that the remaining 98% may seek similar outcomes for different reasons is a much stronger strategic decision.
Feeling satisfied until the next meal, avoiding a 4pm hunger dip, or eating less while eating better do not require a medical target. GLP-1 simply makes these needs easier to articulate.
The question is therefore not “should we target GLP-1 users?” It is “what does their existence finally make sayable for everyone else?”
The question for next week's leadership meeting
Is our nutritional density a promise we know how to articulate, or a statement we tolerate on the back of the pack?
If nobody can express it in one sentence without reading the label, the problem is not nutritional. It is strategic.